Latest Market News

The a2 Milk Company has responded to an ASX price query denying any undisclosed information behind recent share price moves, attributing the volatility to China’s latest birth statistics.

Phoslock Environmental Technologies has amended its December 2025 quarterly report to correct funding data and withdraw its sales outlook, while reporting improved cash flow and resuming factory operations.

Alice Queen Limited (AQX) has had its trading suspension lifted immediately following its response to an ASX Price Query, reopening access for investors.

Alice Queen Limited has addressed a recent doubling in its share price, attributing the surge to rising gold prices and ongoing project developments rather than undisclosed information.

Region Group has announced Greg Chubb as its new CEO and Managing Director, effective 9 March 2026, succeeding Anthony Mellowes who will step back from daily operations a day earlier.

Love Group Global Ltd has reported record operating profits in Q2 FY26, driven by growth in Hong Kong and marketing efficiencies, while planning to expand its matchmaking services into new international markets.

Finder Energy has completed its acquisition of the Petrojarl I FPSO, issuing over 37 million shares to Amplus Energy as part of the US$15 million deal. Amplus’ Managing Director joins Finder’s board, signalling deeper collaboration.

Arena REIT has announced an ordinary quarterly dividend of AUD 0.048125 per security, payable on 5 February 2026, alongside a Dividend Reinvestment Plan priced at AUD 3.50330, offering investors a 1.5% discount.

Oakajee Corporation’s recent aircore drilling at Paynes Find has revealed a new gold mineralised shear zone with assays up to 925ppb Au, extending the project’s exploration potential beneath lake cover.

DXN Limited has signed a strategic MOU with Super Sistem Indonesia to form a joint venture targeting Indonesia’s rapidly expanding digital infrastructure market, aiming for US$7 million in revenue over three years.

Mesoblast has received encouraging feedback from the FDA on its cell therapy rexlemestrocel-L, showing meaningful pain relief and potential opioid use reduction in chronic low back pain patients. The company’s ongoing Phase 3 trial aims to confirm these benefits and advance regulatory approval.

Mitchell Asset Management challenges Identitii Limited’s recent rights issue, alleging it could unfairly boost Beauvais Capital’s stake close to 50%, sparking a potential showdown at the Takeovers Panel.